

Market Applicability/Effective Date															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	N/A

\*FHK- Florida Healthy Kids

## Tecfidera (dimethyl fumarate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Tecfidera (dimethyl fumarate) Starter Kit	One time fill (30 day supply)
Tecfidera (dimethyl fumarate) 120mg delayed release capsules	14 capsules (starting dose; one time fill)
Tecfidera (dimethyl fumarate) 240mg delayed release capsules	2 capsules per day (maintenance dose)

### APPROVAL CRITERIA

Tecfidera (dimethyl fumarate) may be approved when the following criterion is met:

- I. Individual has a diagnosis of relapsing-remitting multiple sclerosis (RRMS).

Tecfidera (dimethyl fumarate) may **not** be approved for the following:

- I. Concurrent use with other MS disease modifying agents (such as Aubagio, Gilenya, Tysabri, Lemtrada, Zinbryta, Copaxone/Glatopa, Extavia, Rebif, Avonex, Plegridy, or Betaseron).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

### Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com> Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed on: July 12, 2017.

Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. *Lancet Neurol*. 2012; 11:420-28. DOI: [http://dx.doi.org/10.1016/S1474-4422\(12\)70056-X](http://dx.doi.org/10.1016/S1474-4422(12)70056-X).

DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Goodin DS, Frohman EM, Garmany Jr. GP, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology*. 2002; 58(2): 169-178. Reaffirmed on: July 19, 2008. Available from: <http://www.neurology.org/content/58/2/169.full>. Accessed on: July 12, 2017.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

PAGE 1 of 1 01/22/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0018-18